Aardvark Therapeutics Files IPO Amendment

Ticker: AARD · Form: S-1/A · Filed: Feb 6, 2025 · CIK: 1774857

Aardvark Therapeutics, INC. S-1/A Filing Summary
FieldDetail
CompanyAardvark Therapeutics, INC. (AARD)
Form TypeS-1/A
Filed DateFeb 6, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$16.00, $18.00, $13.6 million, $7.2 m, $5.2 million
Sentimentneutral

Sentiment: neutral

Topics: ipo, biotech, sec-filing

TL;DR

Aardvark Therapeutics IPO filing updated. Get ready for potential biotech stock action.

AI Summary

Aardvark Therapeutics, Inc. filed an S-1/A amendment on February 6, 2025, for its initial public offering. The company, located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122, is seeking to register its securities under the Securities Act of 1933. The filing details its corporate structure, business operations, and financial information as part of the IPO process.

Why It Matters

This S-1/A filing indicates Aardvark Therapeutics is moving forward with its plan to become a publicly traded company, which could provide significant capital for its drug development pipeline.

Risk Assessment

Risk Level: medium — Biotech IPOs carry inherent risks due to the speculative nature of drug development and market volatility.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

This is an amendment (S-1/A) to Aardvark Therapeutics, Inc.'s initial registration statement (FORM S-1) filed with the SEC, indicating updates or revisions to their IPO plans.

Who is the CEO of Aardvark Therapeutics, Inc.?

Tien-Li Lee, M.D. is listed as the Chief Executive Officer.

What is the company's principal executive office address?

The principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122.

When was this amendment filed?

This amendment was filed on February 6, 2025.

What is the SEC file number for this registration?

The SEC file number is 333-284440.

Filing Stats: 4,491 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2025-02-06 16:02:06

Key Financial Figures

Filing Documents

Underwriting

Underwriting Discounts and Commissions (1) Proceeds to Aardvark Per Share $ $ $ Total $ $ $ (1) See the section titled Underwriters for a description of the compensation payable to the underwriters. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 883,200 shares of our common stock solely to cover over-allotments, if any. At our request, the underwriters have reserved up to 5% of the shares of our common stock offered by this prospectus for sale at the initial public offering price through a directed share program to our directors and officers and certain of our employees, business associates, investors and friends and family of our directors, officers, employees, business associates and investors. See UnderwritersDirected Share Program. Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock to purchasers on , 2025. MORGAN STANLEY BOFA SECURITIES CANTOR RBC CAPITAL MARKETS , 2025 Table of Contents TABLE OF CONTENTS PROSPECTUS PAGE PROSPECTUS SUMMARY 1

RISK FACTORS

RISK FACTORS 12 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 87 MARKET AND INDUSTRY DATA 90

USE OF PROCEEDS

USE OF PROCEEDS 91 DIVIDEND POLICY 93 CAPITALIZATION 94

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 99

BUSINESS

BUSINESS 116 MANAGEMENT 163

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 175 PAGE CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 195 PRINCIPAL STOCKHOLDERS 199

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 202 SHARES ELIGIBLE FOR FUTURE SALE 209 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 212 UNDERWRITERS 217 LEGAL MATTERS 228 EXPERTS 228 WHERE YOU CAN FIND ADDITIONAL INFORMATION 228 INDEX TO FINANCIAL STATEMENTS F-1 Through and including , 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. You should rely only on the information contained in this prospectus and any free writing prospectus that we may provide to you in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with different information or to make any other representations, and we and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only under circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in th

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing